newsfilter
← Latest News
Business Wire·

Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress

Initiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects Received regulatory direction on